Those Who Suffer Much, Know Much 2010 - User Control Panel

through SammyJo’s LDNers.org, assisted by AcceleratedCure.org andsupported by LDN advocates.Two advocates have published books: The first was ‘Up the Creek with aPaddle’ by Mary Boyle-Bradley (20) , and the second, ‘The Promise of Low DoseNaltrexone’ by Elaine Moore and Samantha Wilkinson.All of these activities have contributed to increased awareness, however; withincreased awareness comes increased risk. The upside of the proliferation ofLDN information over the internet is that it enhances awareness of thistreatment option - the downside is that it increases the risk of misinformationand infiltration by competing and conflicting interests.Why the focus on Clinical Trials?Clinical trials seek to answer the ‘who, what, why, where, how, and when’questions that establish patient profile, efficacy, safety, optimum dose andtime. Clinical trials are supposed to establish evidence of successful, safeoutcomes or unsuccessful, unsafe outcomes.Clinical trial data is submitted to federal drug regulators for evaluation prior toa drug being ‘approved’ to treat an identified disease or condition. Doctorstherefore, quite rightly, base treatment decisions on approved drugs that havebeen clinically trialed, because at present, this is still the safest system tofollow.Due to the absence of randomized clinical trial and public health system dataon the Low Dose Naltrexone (LDN) Treatment Protocol, it has not achievedmainstream scientific acceptance as a treatment option for MS or many of theother diseases it has been benefiting. To-date, naltrexone remains recognizedonly as a treatment for drug addiction.Opioid drugs are prescribed legally to relieve pain but they’re also takenillegally for recreation/pleasure. Both avenues can lead to addiction. Naltrexoneis approved as a treatment for drug and alcohol dependence because of itscapacity to block opioid receptors, and for that application it’s usuallyprescribed in 50mg doses several times a day (around 150mg per day): Thirtytimes the low dose range of 3mg to 4.5mg.The length of time opioid receptors are blocked depends on variable factors likesize of dose and speed of individual metabolisation, however; while receptorsremain blocked, opioid drugs cannot attach to their target opioid receptors andthe body is therefore, unable to assimilate the opioid drug’s effects - hence, nopleasure gained from taking the opioid drug.The only known naltrexone safety issues relate to a study on naltrexoneadministered in doses of 300mg per day, which showed adverse effects on the Case Health Pty LtdRevised – July 2007, July 2008, July 2009, July 2010Page 12/433